systematic review meta-analysis network meta-analysis
 

     

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultchange in HbA1c (%)Adverse events leading to treatment discontinuation

diabetes type 2  

NCT00101673      NCTvildagliptin -
Pan, 2008      NCTvildagliptin monotherapyacarboseLow risk of bias -
Foley, 2009      NCTvildagliptin monotherapygliclazideLow risk of bias -
Filozof, 2009      NCTvildagliptingliclazide (add on MET)Low risk of bias -
Matthews , 2010     vildagliptinglimepiride (add on MET)Low risk of bias -
CLAF237A 23104    NCTvildagliptin + METMET -
Schweizer, 2009      NCTvildagliptinmetformin -
Scherbaum [2], 2008          NCTvildagliptinplaceboLow risk of bias negative124%
Mimori, 2006   vildagliptinplacebo -
NCT00351832    NCTvildagliptinplacebo -
Rosenstock, 2008      NCTvildagliptinplaceboLow risk of bias -
Pi-Sunyer, 2007      NCTvildagliptin monotherapyplaceboLow risk of bias suggesting338%
Pratley, 2006     vildagliptin monotherapyplaceboLow risk of bias negative∞%
Ristic, 2005     vildagliptin monotherapyplacebonegative-40%
Dejager [1], 2007      NCTvildagliptin monotherapyplaceboLow risk of bias negative1%
Foley, 2011      NCTvildagliptin monotherapyplacebo -
Kikuchi, 2009     vildagliptin monotherapyplacebo -
Ahren, 2009    NCTvildagliptin monotherapyplacebo -
Lukashevich , 2011     vildagliptinplacebo (add on current therapy) -
Kikuchi, 2010      NCTvildagliptinplacebo (add on glimepiride)Low risk of bias -
Fonseca , 2008     vildagliptinplacebo (add on insulin) -
Fonseca, 2007      NCTvildagliptinplacebo (add on insulin)Low risk of bias suggesting850%
Ahren, 2004     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007      NCTvildagliptinplacebo (add on MET)Low risk of bias negative73%
Goodman, 2009     vildagliptinplacebo (add on MET)Low risk of bias negative
NCT00728351    NCTvildagliptinplacebo (add on MET) -
NCT00494884 (Wollmer)    NCTvildagliptinplacebo (add on MET) -
Bosi, 2009      NCTvildagliptinplacebo (add on MET) -
NCT00822211    NCTvildagliptinplacebo (add on MET) -
NCT00396071    NCTvildagliptinplacebo (add on MET) -
Garber, 2008      NCTvildagliptinplacebo (add on SU)Low risk of bias -
Garber, 2007      NCTvildagliptinplacebo (on top pioglitazone)negative25%
Rosenstock, 2009    NCTvildagliptinrosiglitazoneLow risk of bias -
Ferrannini, 2009      NCTvildagliptinSulfonylurea (add on to MET)Low risk of bias suggesting
GALIANT (Blonde), 2009      NCTvildagliptinTZD (add on MET) -
NCT00368134    NCTvildagliptinvoglibose -
Iwamoto, 2010     vildagliptinvogliboseLow risk of bias -
Schweizer, 2007        NCTvildagliptinmetforminnegative-42%
Goke, 2008     vildagliptinmetformin -
Rosenstock** (vilda vs pio), 2007      NCTvildagliptin monotherapypioglitazoneLow risk of bias -
Bolli, 2008        NCTvildagliptinpioglitazone (add on MET)Low risk of bias negative-5%
Rosenstock** (vilda + pio vs pio), 2007      NCTvildagliptinplacebo (add on TZD)Low risk of bias negative-53%
Rosenstock* (vilda vs rosi), 2007        NCTvildagliptinrosiglitazoneLow risk of bias -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons